NOT FOR DISSEMINATION TO U.S. WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
BLACKFALDS, Alberta, Aug. 17, 2017 (GLOBE NEWSWIRE) -- Hemostemix Inc.
("Hemostemix" or the "Company") (TSX VENTURE:HEM) today announced that it has reached an
agreement with Hemostemix (Asia) Corporation ("HEMA") to definitively resolve all outstanding matters with HEMA
including the litigation against the Company being carried on by HEMA.
As part of the agreement, the Company has agreed to pay HEMA an amount based on expenses incurred based on the
strategic alliance formed between the Company and HEMA in 2015, together with a payment of certain legal fees of HEMA incurred in
connection with the litigation against the Company.
The payment based on expenses is to be $217,000 and made by way of the issuance of common shares in the capital
of the Company. The Company expects to treat the transaction with HEMA as another one of the previously announced series of shares
for debt transactions with certain of the Company’s creditors in full satisfaction of certain trade payables and other debts
payable to be concluded in connection with the Company’s previously announced offerings of subscription receipts of the Company
comprised of: (i) a private placement; and (ii) concurrent rights offering (the “Offering”). The legal fees
are to be paid for in cash.
Pursuant to the agreement, subject only to the receipt of the payments, HEMA will release all claims against the
Company, HEMA’s litigation (which included a USD$50 million loss of income claim) will be discontinued on a without costs basis and
the strategic alliance between the Company and HEMA will be terminated.
Reaching this agreement to resolve matters with HEMA represents a significant milestone in the efforts that have
been made towards the reorganization and transition of the Company's affairs that began with the engagement of Drive Capital to
provide management services in December of 2016.
Kyle Makofka, Chief Restructuring Officer commented, "It is unfortunate that we have not been able to fully
capitalize on all of the time, effort and resources spent in pursuing the strategic alliance with HEMA and its principals,
including Mr. Jim Brown and we thank him for his past support for the Company, including his service as a director." Mr.
Makofka stated further, "However, definitively resolving these matters should ultimately be a positive step for all involved.
In addition, the conclusion of these matters will strategically allow the Company to pursue fresh opportunities in Asia, not only
in Taiwan, China and South Korea, which were directly addressed by the agreements with HEMA, but also potentially Thailand,
Indonesia and Japan as well."
The shares for debt for HEMA are to be issued at a deemed price equivalent to the Offering price, being $0.05 or
such other price as may be dictated by the TSX Venture Exchange. The obligations of the parties hereunder are subject to acceptance
of the terms of the issuance of the shares for debt to HEMA by the TSX Venture Exchange and all other required regulatory
approvals.
ABOUT HEMOSTEMIX INC.
Hemostemix is a public clinical-stage biotechnology company that develops and commercializes innovative
blood-derived cell therapies for medical conditions not adequately addressed by current treatments. It is the first clinical-stage
biotech company to test a stem-cell therapy in an international, multicenter, phase 2 clinical trial for patients with critical
limb ischemia (CLI), a severe form of peripheral artery disease (PAD) caused by reduced blood flow to the legs. The phase 2 trial
targets a participant's diseased tissue with proprietary cells grown from his or her blood that can support the formation of new
blood vessels.
Hemostemix Inc. is traded on the TSX Venture Exchange under the trading symbol HEM. To
find out more visit hemostemix.com or email office@hemostemix.com.
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under
the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This release may contain forward-looking statements. Forward-looking statements are statements that are not
historical facts and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes,"
"intends," "estimates," "projects," "potential," and similar expressions, or that events or conditions "will," "would," "may,"
"could," or "should" occur. Although Hemostemix believes the expectations expressed in such forward-looking statements are based on
reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from
those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates, and opinions of Hemostemix
management on the date such statements were made. By their nature forward-looking statements are subject to known and
unknown risks, uncertainties, and other factors which may cause actual results, events or developments to be materially different
from any future results, events or developments expressed or implied by such forward-looking statements. Such factors
include, but are not limited to, the Company's stage of development, long-term capital requirements and future ability to fund
operations, future developments in the Company's markets and the markets in which it expects to compete, risks associated with its
strategic alliances and the impact of entering new markets on the Company's operations. Each factor should be considered
carefully and readers are cautioned not to place undue reliance on such forward-looking statements. Hemostemix expressly
disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information,
future events, or otherwise.
Contact: Kyle Makofka, Chief Restructuring Officer Bay 1, 5220 Duncan Avenue, PO Box 10 Blackfalds, Alberta T0M 0J0 Phone: (403) 506-3373 E-Mail: kmakofka@drivecapital.ca
